[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-335060-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-335060-en":131},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","activating-point-mutations-in-the-met-kinase-domain-represent-a-unique-molecular-subset-of-lung-cancer-and-other-malignancies-targetable-with-met-inhibitors","Activating Point Mutations in the MET Kinase Domain Represent a Unique Molecular Subset of Lung Cancer and Other Malignancies Targetable with MET Inhibitors","","Activating point mutations in the MET tyrosine kinase domain (TKD) drive oncogenesis in a molecular subset of papillary renal cell carcinomas. Using comprehensive genomic profiling across more than 600,000 patients, the study identifies activating MET TKD point mutations as putative oncogenic drivers across diverse cancer types. Most common oncogenic or likely oncogenic substitutions include residues H1094, L1195, F1200, D1228, Y1230, and M1250, with frequency around 0.5%. Preclinical modeling confirms oncogenicity and reveals distinct sensitivity patterns to type I versus type II MET inhibitors, including partial responses in metastatic lung adenocarcinoma.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/activating-point-mutations-in-the-met-kinase-domain-represent-a-unique-molecular-subset-of-lung-cancer-and-other-malignancies-targetable-with-met-inhibitors/335060/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/activating-point-mutations-in-the-met-kinase-domain-represent-a-unique-molecular-subset-of-lung-cancer-and-other-malignancies-targetable-with-met-inhibitors/335060.png","ImageObject",300,407,{"name":42,"@type":43},"Liam","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-04","2026-09-21",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",12,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What are the main oncogenic mutations studied in the MET kinase domain?","Question",{"text":63,"@type":64},"The document focuses on activating point mutations in the MET tyrosine kinase domain (TKD). The most common oncogenic or likely oncogenic substitutions occur at residues such as H1094, L1195, F1200, D1228, Y1230, and M1250.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How was the frequency of MET TKD mutations estimated?",{"text":68,"@type":64},"The study uses comprehensive genomic profiling among more than 600,000 patients and reports a frequency of approximately 0.5% for activating MET TKD point mutations.",{"name":70,"@type":61,"acceptedAnswer":71},"Do MET TKD mutations respond differently to different classes of MET inhibitors?",{"text":72,"@type":64},"Yes. Preclinical modeling demonstrates differential sensitivity patterns to type I versus type II MET inhibitors, indicating that the mutation-defined alterations can predict response patterns.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},335060,1790014825,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,120,123,127],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":124,"doc_module":4,"doc_module_name":25,"category_name":125,"show_sort_weight":124,"slug":126},10,"Lifestyle","lifestyle",{"id":128,"doc_module":4,"doc_module_name":25,"category_name":129,"show_sort_weight":97,"slug":130},19,"General","general",{"code":4,"msg":82,"data":132},{"doc_id":79,"user_id":133,"nickname":42,"user_avatar":134,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":140,"language":141,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":12,"update_tm":145,"read_time":146,"preview_page_count":4},8796095461564,"https://ap-avatar.wpscdn.com/davatar_155a257f0dc6eb9ab79c44ca47cae57d","ReseaRch aRticle  \nActivating Point Mutations in the MET Kinase Domain Represent a Unique Molecular Subset of Lung Cancer and Other Malignancies Targetable with MET Inhibitors   \nFederica Pecci1, Seshiru Nakazawa1, Biagio Ricciuti1, Guilherme Harada2, Jessica K. Lee3, Joao V. Alessi1, Adriana Barrichello1, Victor R. Vaz1, Giuseppe Lamberti1, Alessandro Di Federico1, Malini M. Gandhi1, Dimitris Gazgalis4, William W. Feng1, Jie Jiang1, Simon Baldacci1, Marie-Anaïs Locquet1, Felix H. Gottlieb1, Monica F. Chen2, Elinton Lee1, Danielle Haradon1, Anna Smokovich1, Emma Voligny1, Tom Nguyen1,  \nVikas K. Goel5, Zachary Zimmerman5, Sumandeep Atwal5, Xinan Wang6, Magda Bahcall1, Rebecca S. Heist7, Sumaiya Iqbal8, 9, Nishant Gandhi10, Andrew Elliott10, Ari M. Vanderwalde10, Patrick C. Ma11, Balazs Halmos12, Stephen V. Liu13, Jianwei Che4, Alexa B. Schrock3, Alexander Drilon2, Pasi A. Jänne1, and Mark M. Awad1  \nActivating point mutations in the MET tyrosine kinase domain (TKD) are oncogenic  \nin a subset of papillary renal cell carcinomas. Here, using comprehensive genomic profiling among >600,000 patients, we identify activating MET TKD point mutations as putative oncogenic driver across diverse cancers, with a frequency of ∼ 0.5%. The most common mutations in the MET TKD defined as oncogenic or likely oncogenic according to OncoKB resulted in amino acid substitutions at positions H1094, L1195, F1200, D1228, Y1230, M1250, and others. Preclinical modeling of these alterations confirmed their oncogenic potential and also demonstrated differential patterns of sensitivity to type I and type II MET inhibitors. Two patients with metastatic lung adenocarcinoma harboring MET TKD mutations (H1094Y, F1200I) and no other known oncogenic drivers achieved confirmed partial responses to a type I MET inhibitor. Activating MET TKD mutations occur in multiple malignancies and may confer clinical sensitivity to currently available MET inhibitors.  \nSIgnIfICAnCE: The identification of targetable genomic subsets of cancer has revolutionized precision oncology and offers patients treatments with more selective and effective agents. Here, we demonstrate that activating, oncogenic MET tyrosine kinase domain mutations are found across a diversity of cancer types and are responsive to MET tyrosine kinase inhibitors.  \nintRoduction  \nThe discovery of new targetable genomic alterations continues to advance the field of precision oncology across cancer types. Dysregulation ofMET gene signaling can occur through a variety of molecular mechanisms, which can be targeted using novel therapeutic strategies (1–3) . MET exon 14 skipping (METex14) alterations, which occur in ∼3% of non–small cell lung cancers (NSCLC) and lead to impaired degradation of the MET receptor, are targetable with MET tyrosine kinase inhibitors (TKI) such as capmatinib and tepotinib, and may also be sensitive to the EGFR:MET bispecific antibody amivantamab (1, 4) . Variants in the extracellular SEMA domain of MET have also been reported to have tumorigenic potential in lung cancers (5, 6) . MET gene amplification has been  \n1Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts. 2Department of Medical Oncology, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, New York.  \n3Foundation Medicine, Cambridge, Massachusetts. 4Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, Massachusetts. 5Turning Point Therapeutics, Bristol Myers Squibb Company, San Diego, California.  \n6Department of Environmental Health, Harvard T.H. Chan School of Public Health, Harvard University, Boston, Massachusetts. 7Massachusetts General Hospital, Boston, Massachusetts. 8The Center for the Development of Therapeutics, Broad Institute of MIT and Harvard, Cambridge, Massachusetts. 9Analytic and Translational Genetics Unit, Massachusetts General Hospital, Boston, Massachusetts. 10Caris Life Sciences, Phoenix, Arizona.  \n11Penn State Cancer Insti","cbCaifwJHXbz8MAu","https://ap.wps.com/l/cbCaifwJHXbz8MAu","pdf",10029042,17,"English","# Introduction\n## MET alterations and prior targetable mechanisms\n# Results\n## Type and frequency of MET TKD","[{\"question\":\"What are the main oncogenic mutations studied in the MET kinase domain?\",\"answer\":\"The document focuses on activating point mutations in the MET tyrosine kinase domain (TKD). The most common oncogenic or likely oncogenic substitutions occur at residues such as H1094, L1195, F1200, D1228, Y1230, and M1250.\"},{\"question\":\"How was the frequency of MET TKD mutations estimated?\",\"answer\":\"The study uses comprehensive genomic profiling among more than 600,000 patients and reports a frequency of approximately 0.5% for activating MET TKD point mutations.\"},{\"question\":\"Do MET TKD mutations respond differently to different classes of MET inhibitors?\",\"answer\":\"Yes. Preclinical modeling demonstrates differential sensitivity patterns to type I versus type II MET inhibitors, indicating that the mutation-defined alterations can predict response patterns.\"}]","Activating Point Mutations in the MET Kinase Domain Represent a Unique Molecular Subset of Lung Cancer and Other Malignancies Targetable with MET Inhibitors | PDF",1790009524,43]